- Home
- STRO vs CTSO Comparison
STRO vs CTSO Comparison
Compare STRO & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- CTSO
- Stock Information
- Founded
- STRO 2003
- CTSO 1997
- Country
- STRO United States
- CTSO United States
- Employees
- STRO N/A
- CTSO N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- CTSO Medical/Dental Instruments
- Sector
- STRO Health Care
- CTSO Health Care
- Exchange
- STRO Nasdaq
- CTSO Nasdaq
- Market Cap
- STRO 69.1M
- CTSO 72.8M
- IPO Year
- STRO 2018
- CTSO N/A
- Fundamental
- Price
- STRO $0.86
- CTSO $0.89
- Analyst Decision
- STRO Hold
- CTSO Buy
- Analyst Count
- STRO 8
- CTSO 2
- Target Price
- STRO $3.83
- CTSO $5.50
- AVG Volume (30 Days)
- STRO 428.5K
- CTSO 351.0K
- Earning Date
- STRO 08-07-2025
- CTSO 08-07-2025
- Dividend Yield
- STRO N/A
- CTSO N/A
- EPS Growth
- STRO N/A
- CTSO N/A
- EPS
- STRO N/A
- CTSO N/A
- Revenue
- STRO $104,473,000.00
- CTSO $36,107,520.00
- Revenue This Year
- STRO N/A
- CTSO $11.15
- Revenue Next Year
- STRO N/A
- CTSO $21.39
- P/E Ratio
- STRO N/A
- CTSO N/A
- Revenue Growth
- STRO N/A
- CTSO 20.18
- 52 Week Low
- STRO $0.52
- CTSO $0.71
- 52 Week High
- STRO $5.17
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- STRO 55.54
- CTSO 41.50
- Support Level
- STRO $0.76
- CTSO $1.03
- Resistance Level
- STRO $0.83
- CTSO $1.19
- Average True Range (ATR)
- STRO 0.07
- CTSO 0.09
- MACD
- STRO 0.01
- CTSO 0.01
- Stochastic Oscillator
- STRO 52.25
- CTSO 27.21
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.